Trial Profile
Phase1a, Randomized Placebo-controlled, Single and Multiple Dose, Dose-escalation Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNI-362 in Healthy Aged Volunteers 50 to 72 Years of Age
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 20 Feb 2023
Price :
$35
*
At a glance
- Drugs NNI-362 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions; First in man
- Sponsors Neuronascent
- 08 Nov 2022 According to Neuronascent media release, this study was fully supported by a grant from the National Institute on Aging (NIA, part of the National Institute of Health).
- 08 Nov 2022 According to Neuronascent media release, the company announced its abstract entitled "Reduction of plasma p-Tau181 from a Phase 1a Randomized Trial of NNI-362 in a healthy aged population consistent with amelioration of tau hyperphosphorylation in human differentiated neuron cultures" has been accepted for a poster presentation at the 15th Clinical Trials on Alzheimer's Disease (CTAD 2022) to be held in San Francisco, California, USA from 29th November to 2nd December 2022.
- 08 Nov 2022 Results published in the Neuronascent media release.